Securities code: 300705 securities abbreviation: Hunan Jiudian Pharmaceutical Co.Ltd(300705)
Announcement No.: 2022-011
Bond Code: 123110 bond abbreviation: Jiudian convertible bond
Hunan Jiudian Pharmaceutical Co.Ltd(300705)
Annual performance forecast for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected performance: □ turn loss into profit, increase in the same direction □ decrease in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to listed companies: 195 million yuan – 218 million yuan
Net profit of shareholders: 82.2598 million yuan, an increase of 137.05% – 165.01% over the same period of last year
Profit after deducting non recurring losses: 175 million yuan – 195 million yuan
Net profit after profit: 67.2464 million yuan, an increase of 160.24% – 189.98% over the same period of last year
2、 Communication with accounting firms
The data related to the performance forecast is the preliminary calculation result of the company’s financial department. Without the audit of the accounting firm, the company has pre communicated with the accounting firm on the matters related to the performance forecast. There is no difference between the company and the accounting firm in the performance forecast, and the specific data shall be subject to the audit result.
3、 Explanation of performance change reasons
During the reporting period, the company closely followed the reform trends of national pharmaceutical policies. On the basis of fully mastering the market information and combined with the company’s competitive advantages, the company formulated targeted marketing strategies, continuously explored the market and cultivated star products in the field of high-end transdermal patches. The main business income, net profit and other important financial indicators increased significantly compared with the same period of last year. At the same time, the company grasps the development trend of the pharmaceutical industry, actively expands cdmo business and adds new technology transfer
And technical service income.
The non recurring profit and loss during the reporting period is expected to be 20-25 million yuan, which is mainly due to the government reward obtained by the company through consistency evaluation.
4、 Other relevant instructions
This performance forecast is the result of the preliminary calculation of the company’s financial department. Without the audit of the audit institution, the specific financial data will be disclosed in detail in the 2021 annual report. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Hunan Jiudian Pharmaceutical Co.Ltd(300705) board of directors January 29, 2022
